Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tenax Therapeutics (TENX) Shares Outstanding (Diluted Average) (2023 - 2026)

Tenax Therapeutics' Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $28.1 million for Q1 2015.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 382.39% to $28.1 million in Q1 2015 year-over-year; TTM through Jan 2015 was $28.1 million, a 382.39% increase, with the full-year FY2014 number at $9.4 million, up 432.23% from a year prior.
  • Shares Outstanding (Diluted Average) hit $28.1 million in Q1 2015 for Tenax Therapeutics, roughly flat from $28.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for TENX hit a ceiling of $29.7 million in Q1 2012 and a floor of $1.4 million in Q2 2012.
  • Historically, Shares Outstanding (Diluted Average) has averaged $14.1 million across 5 years, with a median of $9.4 million in 2014.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): plummeted 94.28% in 2013 and later skyrocketed 1151.51% in 2014.
  • Tracing TENX's Shares Outstanding (Diluted Average) over 5 years: stood at $26.0 million in 2011, then crashed by 93.41% to $1.7 million in 2012, then skyrocketed by 107.68% to $3.6 million in 2013, then skyrocketed by 688.37% to $28.0 million in 2014, then grew by 0.1% to $28.1 million in 2015.
  • Business Quant data shows Shares Outstanding (Diluted Average) for TENX at $28.1 million in Q1 2015, $28.0 million in Q4 2014, and $27.7 million in Q3 2014.